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Abstract
Background: Studies of the efficacy of vitamin C treatment for fatigue have yielded inconsistent results. One of
the reasons for this inconsistency could be the difference in delivery routes. Therefore, we planned a clinical trial
with intravenous vitamin C administration.
Methods: We evaluated the effect of intravenous vitamin C on fatigue in office workers. A group of 141 healthy
volunteers, aged 20 to 49 years participated in this randomized, double-blind, controlled clinical trial. The trial
group received 10 grams of vitamin C with normal saline intravenously, while the placebo group received normal
saline only. Since vitamin C is a well-known antioxidant, oxidative stress was measured. Fatigue score, oxidative
stress, and plasma vitamin C levels were measured before intervention, and again two hours and one day after
intervention. Adverse events were monitored.
Results: The fatigue scores measured at two hours after intervention and one day after intervention were
significantly different between the two groups (p = 0.004); fatigue scores decreased in the vitamin C group after
two hours and remained lower for one day. Trial also led to higher plasma vitamin C levels and lower oxidative
stress compared to the placebo group (p < 0.001, p < 0.001, respectively). When data analysis was refined by
dividing each group into high-baseline and low-baseline subgroups, it was observed that fatigue was reduced in
the lower baseline vitamin C level group after two hours and after one day (p = 0.004). The same did not hold for
the higher baseline group (p = 0.206).
Conclusion: Thus, intravenous vitamin C reduced fatigue at two hours, and the effect persisted for one day. There
were no significant differences in adverse events between two groups. High dose intravenous vitamin C proved to
be safe and effective against fatigue in this study.
Trial Registration: The clinical trial registration of this trial is http://ClinicalTrials.govNCT00633581.
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Background
Fatigue is one of the most common complaints in daily
life, and the prevalence of fatigue is high in full-time
workers. Previous studies have shown that 27% of adults,
who were weekly assessed, experienced fatigue [1], and
32.5% of patients who visited primary care clinics com-
plained of fatigue [2]. Oxidative stress is thought to
underlie fatigue to some extent; serum markers of oxida-
tive stress are associated with symptoms of chronic
fatigue syndrome, including asthenia after physical activ-
ity and arthralgias [3]. Such markers of oxidative stress
include reactive oxygen species (ROS) and cytokines [4].
Vitamin C is a well-known antioxidant. Several studies
have shown that vitamin C can have clinical value in its
role as an antioxidant. For example, vitamin C treatment
attenuates myalgia and reduces the toxicity of some
anticancer agents by reducing oxidative stress [5-8].
Nevertheless, studies of the efficacy of vitamin C supple-
mentation have yielded inconsistent results. Route of
administration is one of the major sources of inconsis-
tency. A recent pharmacokinetic study of oral vitamin C
* Correspondence: lymphych@hanmail.net
7Yeom Primary Care Clinic, Seoul, Republic of Korea
Full list of author information is available at the end of the article
Suh et al. Nutrition Journal 2012, 11:7
http://www.nutritionj.com/content/11/1/7
© 2012 Suh et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.showed that plasma vitamin C concentrations are little
affected by oral administration, because of poor bioavail-
ability [9]. Since there have been few randomized con-
trolled studies evaluating the efficacy of intravenous
vitamin C [10], we sought to reevaluate the effects of
intravenous vitamin C. The purpose of this study was to
determine the efficacy of high dose vitamin C injection
on fatigue in healthy workers, in a randomized controlled
trial.
Materials and methods
Design
This study was a double-blind, random allocated, placebo-
controlled trial conducted at two companies in the Repub-
lic of Korea. Participants were recruited between March
and April 2008. We randomly assigned 73 participants to
the vitamin C group, and 74 participants to the placebo
group. The participants received a single intravenous
treatment of either vitamin C (10 g) or normal saline. The
institutional review board of Dongguk University Ilsan
Hospital approved the protocol, and all patients provided
written informed consent. The clinical trial registration of
this trial is ClinicalTrials.gov NCT00633581.
Setting and Participants
The study was designed to include 150 volunteers (Kor-
ean, office workers or salespeople). The subject size was
estimated based on the results of a pilot study with the fol-
lowing parameters: type I error a = 0.05, power 1-b = 0.8,
and dropout rate = 10%. The sample variance of the
changes in fatigue scores (between pre-trial scores and
scores two hours after intervention) was 3.87; the score is
described in detail below. The average difference in fatigue
score between the vitamin C group and the placebo group
was 0.85 (fatigue score) in our pilot study.
The inclusion criteria were as follows: 1) age 20 to 49
years; 2) full-time worker in the company; 3) apparently
healthy; 4) no vitamin supplement intake during the two
days before enrollment; and 5) voluntary participation.
The exclusion criteria were as follows: 1) acute illness
(such as common cold or acute gastroenteritis); 2) chronic
disease (such as diabetes, hypertension, liver disease, or
renal disease); 3) previous history of renal calculi or gout;
4) current pregnancy or lactation; and 5) hypersensitivity
to vitamins or intravenous injection. The past medical his-
tory was investigated by research nurses and the principal
investigator, a board-certified family physician, performed
physical examination for the participants.
Random Assignment and Interventions
We randomly assigned participants to vitamin C and pla-
cebo groups. A computerized randomization list was gen-
erated by a statistician, sealed in an opaque envelope, and
delivered to a study nurse. The study nurse attached
consecutive numbers (1-150) to the normal saline bottles,
and opened the envelope containing the randomization
list in a closed room. She prepared solutions by mixing
either vitamin C 10 g (20 ml) or normal saline 20 ml in
the normal saline bottle according to the randomization
list, then had no further involvement in the study. Another
study nurse assigned consecutive numbers (1-150) to the
participants in order of enrollment. The solution of the
same number was administered to each participant by the
study nurses. The participants and study nurses assessing
the outcomes were blinded to the group assignment. The
vitamin C group received vitamin C 10 g (20 ml of ascor-
bic acid 500 mg/ml, colorless transparent solution, Merit
C
®, Huons, Korea) in 100 ml of normal saline intrave-
nously over 30 minutes, while the placebo group received
t h es a m ea m o u n t( 1 2 0m l )o fn o r m a ls a l i n ei nt h es a m e
manner. The intervention was performed a single time on
one day.
Outcomes and Follow-up
W em e a s u r e dt h ef a t i g u es c o r eu s i n gan u m e r i cr a t i n g
scale (0-10), with current fatigue (described as “fatigue
right now”) as a primary outcome [11]. The fatigue score
was evaluated three times: before the intervention (base-
line), two hours after intervention, and one day after inter-
vention. We determined oxidative stress levels (Free
Oxygen Radicals Test (FORT) by Free Oxygen Radicals
Monitor Plus, Callegari, Italy) and measured plasma vita-
min C concentration (by High Performance Liquid Chro-
matography, HPLC) at baseline and two hours after the
trial. FORT was repeated one day after the trial. The type
of detector is UV detector (Hewlett-Packard, German),
column used is Cogent(150 mm × 4 mm × 5 um)and the
buffers are cetyltriethylammonium bromide (SIGMA, U.S.
A) and potassium dihydrogen phosphate (DUKSAN,
Korea) for the HPLC.
Assessment of Adverse Events
During intervention and at both post-intervention assess-
ments, study nurses assessed adverse events by asking
open-ended questions. Information collected for each
adverse event included a description of the event, dura-
tion, intensity, required treatment, and outcome.
Statistical Analysis
Analyses were performed with the “intention-to-treat”
method. Predefined primary end-points were the differ-
ences in fatigue scores between two hours after interven-
tion, and one day after intervention. The differences in
fatigue scores were compared between the vitamin C
group and the placebo group using analysis of covariance
(ANCOVA), which included baseline fatigue score as a
covariate to account for individual variations in fatigue
level. As secondary end-points, oxidative stress levels
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with similar adjustment of baseline levels. Using indepen-
dent t-tests, plasma vitamin C concentrations were com-
pared between the two groups at baseline and two hours
after intervention, respectively. For subgroup analyses,
subjects were categorized into two groups (higher and
lower) based on the 50
th percentile of the baseline vita-
min C level. Change in fatigue scores between the trial
and placebo group were analyzed using ANCOVA within
each group.
Statistical analyses were performed using SPSS, ver-
s i o n1 6 . 0 2( S P S S ,C h i c a g o ,I L ,U S A ) .H y p o t h e s i st e s t s
yielding p values less than 0.05 were considered
significant.
Results
Subject Compliance to the Clinical Trial
Of the 150 subjects initially recruited for the trial, 147 (74
in the vitamin C group, 73 in the placebo group) were
enrolled in the final study group. Four participants (two in
each group) dropped out of the study the day after inter-
vention. The dropped participants completed two out-
come measurements (baseline and two hours after
intervention), but did not complete the third measurement
(after 24 hour time point) the next day. Thus, we initially
analyzed data from the remaining 143 participants. Two
outliers (one in each group) for plasma vitamin C level
were excluded from analysis. Our final data set, then,
included 141 participants (70 in the vitamin C group, 71
in the placebo group) (Figure 1). The baseline characteris-
tics of participants are shown in Table 1. There were no
demographical differences between two groups. Lifestyles
can influence fatigue; however, it did not differ between
the two groups.
Impact of Vitamin C on Fatigue
Fatigue scores (indicating participants’ ratings of “fatigue
right now”) were significantly different between the groups
after intervention (p = 0.004, Table 2). There were no sig-
nificant differences among outcomes assessed two hours
after intervention and one day after intervention (data not
shown). We conclude that fatigue was significantly
improved two hours after vitamin C injection and that the
effect persisted one day after the intervention (Figure 2).
However, there were no differences between the two
groups in “usual fatigue” and “worst fatigue” during the
previous 24 hours.
Antioxidant Capacity of Intravenous Vitamin C
Oxidative stress, as the secondary outcome, was signifi-
cantly lower in the vitamin C group than in the placebo
group after intervention (p < 0.001). Plasma vitamin C
levels were also significantly different after intervention
(p < 0.001).
We have observed in our clinic that some patients
with fatigue benefit from vitamin C while others do not;
therefore, we tried to find the characteristics of the
responsive group. We performed subgroup analysis by
categorizing subjects into two subgroups (higher and
lower) based on the 50
th percentile of the baseline vita-
min C level. The 50
th percentile of the baseline vitamin
C level was 10.97 μg/ml in the trial group and 11.88 μg/
ml in the placebo group. We then compared fatigue
scores between the trial and placebo groups, in each
subgroup. Fatigue score was significantly reduced in the
lower group, but not the higher group, compared to pla-
cebo (p = 0.004, p = 0.206, respectively, Table 3).
The dropout rate was low (4/147, or 2.7%), and prema-
ture withdrawal due to adverse events did not occur in
our study. The adverse event profile of the study partici-
p a n t si ss h o w ni nT a b l e4 .T h er a t eo fa d v e r s ee v e n t si n
the vitamin C group during and two hours after interven-
tion was 16/70 (22.9%), which was not significantly differ-
e n tf r o mt h a ti nt h ep l a c e b og r o u p( 1 1 / 7 1 ,1 5 . 4 % ) .T h e
next day, the rate of adverse events in the vitamin C group
was 4/70 (5.7%), which was similar to that in the placebo
group (4/71, 5.6%). The most common adverse event in
both groups was itching and/or pain at the injection site.
The distribution of adverse events did not differ signifi-
cantly between the two groups at two hours after interven-
tion or the next day (p = 0.266, p = 0.984, respectively).
T h e r ew e r en os e r i o u sa d v e r s ee v e n t s ,n o rw e r et h e r e
adverse events that required treatment.
Discussion
The primary outcome, fatigue score (assessing the level
of “fatigue right now”), was significantly decreased in
the vitamin C group compared to the placebo group.
The degree of fatigue improved in the vitamin C group
1 day after intervention as well as at 2 hours after inter-
vention. The effect of vitamin C injection was evident in
subjects with an initially lower vitamin C level and not
in subjects with initially higher levels. Although the
pharmacological effect of vitamin C is known to last 4-6
hours (9), our data demonstrate vitamin C injection to
be effective a day after intervention as well as at 2 hours
after intervention. Previous studies of vitamin C treat-
ment for fatigue have led to disparate results: in some
studies, treatment with vitamin C improved fatigue sig-
nificantly [12,13]; in others, the treatment proved inef-
fective [14-18]. One trial showed that regular vitamin C
infusion reduced fatigue in inpatients with chronic fati-
gue syndrome [12]. In a Korean study, vitamin C injec-
tion (10 g twice a week) improved fatigue in inpatients
with terminal cancer [13]. These trials recruited inpati-
ents with serious diseases, and vitamin C administration
was done more than two times. However, the studies
were all non-comparative trials. In contrast, randomized
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vitamin C was administered orally [14-18].
Until recently, oral and intravenous vitamin C were
regarded as equivalent, but recent data has shown that the
two forms have different pharmacokinetic characteristics
(9, 10). Plasma concentrations of vitamin C following oral
administration are not dose-dependent, and are instead
subject to a plateau. Vitamin C distribution after oral
delivery is tightly controlled by intestinal absorption,
transport to tissues, and renal reabsorption and excretion
[19,20]. A recent pharmacokinetic study using the deple-
tion-repletion method showed that intravenous adminis-
tration could achieve 70-fold higher blood levels of
vitamin C compared to the highest tolerated oral dose (9).
Intravenous administration of vitamin C bypasses the con-
trols described above, and results in high plasma concen-
trations. Although we did not use a depletion-repletion
study design, we measured plasma levels of vitamin C of
267.90 ± 141.83 μg/ml (mean ± SD) two hours after inter-
vention. This level is equivalent to 1521.04 ± 805.25 μmol/
L, overlapping the 1000-1500 μmol/L range predicted
from the pharmacokinetic model for 10 g intravenous
administration [9].
Our subgroup analysis on the effects on the “fatigue
right now” scores indicate that vitamin C injection effi-
cacy is affected by baseline vitamin C levels. Specifically,
Figure 1 Study flow diagram.
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showed a significant response to vitamin C injection
while the subgroup with high baseline levels remained
unaffected. We suggest that vitamin C is especially effec-
tive in subjects with relatively low baseline levels of vita-
min C. Therefore, inconsistent results of previous
studies (12, 13, 14-18) may result from route of admin-
istration, baseline vitamin C levels of subjects, or both.
Our study has some limitations. First, fatigue measure-
ments were acquired only three times, and plasma vita-
min C measurements were made only two times. The
association between vitamin C administration and
fatigue would have been clearer if we had included
more data points in the study. Second, fatigue is a mat-
ter of subjective self-assessment. We reduced subjective
bias by using a validated measurement tool to assess
fatigue [11], and we detected significant differences in
fatigue scores after adjustment of baseline values. These
findings confirm the likelihood of wide individual varia-
tions in fatigue self-assessment. Third, we found no sig-
nificant relationship between fatigue and oxidative
stress. Our participants were healthy adults, so their oxi-
dative stress and fatigue levels might have been too low
to demonstrate a clear relationship. Finally, our partici-
pants were 20 to 49 years of age and served as office
workers and salespeople. Therefore, generalization to
labor workers and elderly (≥ 50 years) workers may be
limited. Although it is desirable to perform some
screening test such as blood chemistry panel, we
excluded subjects having chronic disease by past medical
history. The reason why we select the dose of vitamin C
10 g is that we considered efficacy and safety for general
population. To avoid unexpected adverse reactions, the
least dose for the high dose is ideal and we referred a
preceding domestic study[13].
We suggest that increase in the dosage or frequency of
intravenous vitamin C administration may increase the
treatment efficacy. Further study is required to deter-
mine effective dose ranges of vitamin C for treatment of
fatigue, and serial measurements of fatigue should clarify
effective dosage windows.
Conclusions
We have shown that administration of high dose intra-
venous vitamin C reduced fatigue significantly compared
to placebo in office workers. Moreover, the effect of
intervention was strongest in subjects with lower base-
line levels of vitamin C and, interestingly, the effect
Table 1 Baseline characteristics of participants
Vitamin C Group
(n = 70)
Placebo Group
(n = 71)
P value
Sex, n 0.559
†
Male (%) 31 (44.3) 28 (39.4)
Female (%) 39 (55.7) 43 (60.6)
Age, years (SD) 30.4 (5.7) 31.2 (5.8) 0.427
‡
BMI, kg/m
2 (SD) 21.5 (3.0) 21.8 (3.1) 0.683
‡
Usual fatigue, n 0.971
†
Yes (%) 59 (84.3) 60 (84.5)
No (%) 11 (15.7) 11 (15.5)
Smoking status, n 0.158
†
Smoker (%) 21 (30.0) 14 (19.7)
Nonsmoker (%) 49 (70.0) 57 (80.3)
Drinking status, n 0.448
†
Drinker (%) 56 (80.0) 53 (74.6)
Nondrinker (%) 14 (20.0) 18 (25.4)
Exercise, n 0.495
†
Regular (%) 19 (27.1) 23 (32.4)
Irregular (%) 51 (72.9) 48 (67.6)
Sleeping hours (SD) 6.5 (1.0) 6.4 (0.9) 0.296
‡
†p value from Chi-square test, ‡p value from independent t test, BMI: body
mass index
Table 2 Comparison of fatigue, plasma vitamin C levels, and oxidative stress between the two groups
Vitamin C Group
(n = 70)
Placebo Group
(n = 71)
p
value
‡
Baseline 2 hours after
intervention
1 day after
intervention
Baseline 2 hours after
intervention
1 day after
intervention
Fatigue right now* 5.64 ±
2.02
5.10 ± 2.04 4.97 ± 2.33 5.54 ±
2.07
5.31 ± 2.00 5.66 ± 2.16 0.004
Usual fatigue during the
previous 24 hours
5.59 ±
1.56
- 5.37 ± 2.06 5.77 ±
1.73
- 5.55 ± 1.79 0.870
Worst fatigue during the
previous 24 hours
7.16 ±
1.83
- 6.47 ± 2.13 7.14 ±
1.77
- 6.82 ± 1.97 0.202
Plasma vitamin C level (μg/ml) 12.66 ±
6.50
267.90 ± 141.83 - 12.13 ±
4.99
12.52 ± 5.70 - <
0.001
Oxidative stress (mmol/dl
H2O2)
†
311.76 ±
74.15
184.46 ± 59.41 296.11 ± 64.37 310.89 ±
74.90
327.21 ± 78.80 303.72 ± 81.26 <
0.001
*Fatigue was measured using a numeric rating scale, 0-10.
†Oxidative stress was measured using the Free Oxygen Radicals Test (FORT).
‡p value from ANCOVA.
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Page 5 of 7Figure 2 Boxplots of fatigue scores in the two groups. The mean fatigue scores of the vitamin C group decreased while those of the
placebo group did not.
Table 3 Comparison of fatigue between the two groups within subgroups categorized by baseline vitamin C level
Vitamin C Group
(n = 70)
Placebo Group
(n = 71)
p
value†
Baseline 2 hours after
intervention
1 day after
intervention
Baseline 2 hours after
intervention
1 day after
intervention
Fatigue right
now*
Higher 5.74 ±
1.98
5.26 ± 2.23 5.28 ± 2.40 5.47 ±
2.17
5.25 ± 2.30 5.53 ± 2.22 0.206
Lower 5.54 ±
2.09
4.94 ± 1.85 4.66 ± 2.30 5.60 ±
1.99
5.37 ± 1.68 5.80 ± 2.13 0.004
*Fatigue was measured using a numeric rating scale, 0-10.
Higher and Lower groups were divided by 50th percentile (10.95 μg/ml in trial group, 11.95 μg/ml in placebo group) of baseline plasma vitamin C level.
†p value from ANCOVA with adjustments for the time factor and baseline measurements.
Table 4 Adverse events after intervention
Characteristics Vitamin C Group
(n = 70)
Placebo
Group (n = 71)
Withdrawal from trial for adverse events, n (%) 0 (0) 0 (0)
Patients with ≥ 1 adverse events 2 hours after trial, n (%) 16 (22.9) 11 (15.4)
Patients with ≥ 1 adverse events 1 day after trial, n (%) 4 (5.7) 4 (5.6)
Total adverse events, n 24 17
Patients who experienced specific adverse events 2 hours after intervention, n (%)
itching sense/pain at injection site 9 (12.9) 8 (11.3)
dry mouth 7 (10) 2 (2.8)
others* 4 (5.7) 3 (4.2)
Patients who experienced specific adverse events 1 day after intervention, n (%)
itching sense/pain at injection site 1 (1.4) 3 (4.2)
dry mouth 1 (1.4) 0 (0)
diarrhea 1 (1.4) 0 (0)
common cold symptoms 1 (1.4) 1 (1.4)
*Other adverse events included chest discomfort, palpitations, sweating, and abdominal discomfort in the vitamin C group and dizziness, fatigue, and myalgias in
the placebo group. These adverse events occurred in one case each.
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clinical implications. Patients with severe fatigue, such
as cancer inpatients, and patients at risk for vitamin C
deficiency, would exhibit better responses.
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